Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
Scorpius Holdings (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), has been selected to join the Medical CBRN Defense Consortium (MCDC). The MCDC, established in 2015 under the U.S. Department of Defense, focuses on advancing medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats.
As a member, Scorpius will contribute its proprietary expertise to accelerate innovations addressing CBRN threats. This membership allows Scorpius to engage with government stakeholders, collaborate with other companies and academic institutions, and pursue funding opportunities aligned with the DoD's medical CBRN defense priorities.
Jeff Wolf, CEO of Scorpius, stated that this selection reinforces the company's commitment to developing therapies protecting both military personnel and civilians. The membership represents a significant milestone in Scorpius' efforts to contribute to U.S. biosecurity and national defense.
Scorpius Holdings (NYSE American: SCPX), un'organizzazione integrata di sviluppo e produzione di contratti (CDMO), è stata selezionata per unirsi al Consorzio Medico di Difesa CBRN (MCDC). Il MCDC, istituito nel 2015 sotto il Dipartimento della Difesa degli Stati Uniti, si concentra sull'avanzamento delle contromisure mediche contro le minacce chimiche, biologiche, radiologiche e nucleari (CBRN).
In qualità di membro, Scorpius contribuirà con la sua expertise proprietaria per accelerare le innovazioni che affrontano le minacce CBRN. Questa adesione consente a Scorpius di interagire con le parti interessate del governo, collaborare con altre aziende e istituzioni accademiche, e perseguire opportunità di finanziamento in linea con le priorità di difesa medica CBRN del DoD.
Jeff Wolf, CEO di Scorpius, ha dichiarato che questa selezione rafforza l'impegno dell'azienda nello sviluppo di terapie che proteggano sia il personale militare che i civili. L'adesione rappresenta una significativa pietra miliare negli sforzi di Scorpius per contribuire alla biosicurezza e alla difesa nazionale degli Stati Uniti.
Scorpius Holdings (NYSE American: SCPX), una organización integrada de desarrollo y fabricación de contratos (CDMO), ha sido seleccionada para unirse al Consorcio Médico de Defensa CBRN (MCDC). El MCDC, establecido en 2015 bajo el Departamento de Defensa de los EE. UU., se centra en promover contramedidas médicas contra amenazas químicas, biológicas, radiológicas y nucleares (CBRN).
Como miembro, Scorpius contribuirá con su experiencia propietaria para acelerar innovaciones que aborden las amenazas CBRN. Esta membresía permite a Scorpius interactuar con partes interesadas del gobierno, colaborar con otras empresas e instituciones académicas y buscar oportunidades de financiamiento alineadas con las prioridades de defensa médica CBRN del DoD.
Jeff Wolf, CEO de Scorpius, declaró que esta selección refuerza el compromiso de la empresa de desarrollar terapias que protejan tanto al personal militar como a los civiles. La membresía representa un hito significativo en los esfuerzos de Scorpius por contribuir a la bioseguridad y la defensa nacional de los EE. UU.
Scorpius Holdings (NYSE American: SCPX), 통합 계약 개발 및 제조 조직 (CDMO)로, 의료 CBRN 방어 컨소시엄 (MCDC)에 참여하도록 선택되었습니다. MCDC는 2015년 미국 국방부 산하에 설립되어 화학, 생물학, 방사능 및 핵 (CBRN) 위협에 대한 의료 대책을 발전시키는 데 중점을 두고 있습니다.
회원으로서 Scorpius는 CBRN 위협을 해결하는 혁신을 가속화하기 위해 자체 전문 지식을 기여할 것입니다. 이 회원 자격은 Scorpius가 정부 이해 관계자와 소통하고, 다른 회사 및 학술 기관과 협력하며, DoD의 의료 CBRN 방어 우선 순위에 맞는 자금 지원 기회를 추구할 수 있게 합니다.
Jeff Wolf Scorpius CEO는 이 선택이 군인과 민간인 모두를 보호하는 치료법 개발에 대한 회사의 헌신을 강화한다고 밝혔습니다. 이 회원 자격은 Scorpius가 미국의 생물 보안 및 국가 방어에 기여하기 위한 노력에 있어 중요한 이정표를 나타냅니다.
Scorpius Holdings (NYSE American: SCPX), une organisation intégrée de développement et de fabrication de contrats (CDMO), a été séléctionnée pour rejoindre le Consortium Médical de Défense CBRN (MCDC). Le MCDC, établi en 2015 sous le département de la Défense des États-Unis, se concentre sur l'avancement des contre-mesures médicales contre les menaces chimiques, biologiques, radiologiques et nucléaires (CBRN).
En tant que membre, Scorpius contribuera avec son expertise propriétaire pour accélérer les innovations visant à répondre aux menaces CBRN. Ce statut de membre permet à Scorpius de dialoguer avec les parties prenantes gouvernementales, de collaborer avec d'autres entreprises et institutions académiques, et de rechercher des opportunités de financement en adéquation avec les priorités de défense médicale CBRN du DoD.
Jeff Wolf, PDG de Scorpius, a déclaré que cette sélection renforce l'engagement de l'entreprise à développer des thérapies protégeant à la fois le personnel militaire et les civils. L'adhésion représente une étape significative dans les efforts de Scorpius pour contribuer à la biosécurité et à la défense nationale des États-Unis.
Scorpius Holdings (NYSE American: SCPX), eine integrierte Vertragsentwicklungs- und Produktionsorganisation (CDMO), wurde ausgewählt, um dem Medical CBRN Defense Consortium (MCDC) beizutreten. Das MCDC, das 2015 unter dem U.S. Verteidigungsministerium gegründet wurde, konzentriert sich auf die Förderung medizinischer Gegenmaßnahmen gegen chemische, biologische, radiologische und nukleare (CBRN) Bedrohungen.
Als Mitglied wird Scorpius sein proprietäres Fachwissen einbringen, um Innovationen voranzutreiben, die sich mit CBRN-Bedrohungen befassen. Diese Mitgliedschaft ermöglicht es Scorpius, mit Regierungsvertretern in Kontakt zu treten, mit anderen Unternehmen und akademischen Institutionen zusammenzuarbeiten und Finanzierungsmöglichkeiten zu verfolgen, die mit den medizinischen CBRN-Verteidigungsprioritäten des DoD in Einklang stehen.
Jeff Wolf, CEO von Scorpius, erklärte, dass diese Auswahl das Engagement des Unternehmens zur Entwicklung von Therapien verstärkt, die sowohl Militärangehörige als auch Zivilisten schützen. Die Mitgliedschaft stellt einen bedeutenden Meilenstein in den Bemühungen von Scorpius dar, zur Bio-Sicherheit und nationalen Verteidigung der USA beizutragen.
- Selected to join the Medical CBRN Defense Consortium (MCDC)
- Opportunity to collaborate with government, industry, and academia on medical solutions
- Access to potential funding for projects aligned with DoD priorities
- Expansion into the field of medical countermeasures for CBRN threats
- None.
Insights
Scorpius Holdings' selection to join the Medical CBRN Defense Consortium is a strategic milestone that could significantly enhance the company's position in the biodefense sector. This membership opens doors to valuable collaborations and potential funding opportunities from the Department of Defense, which could drive future revenue growth.
The CBRN defense market is projected to grow substantially, driven by increasing global threats and government investments. Scorpius' expertise in biologics manufacturing aligns well with the consortium's focus on medical countermeasures. This could lead to new contract opportunities and expansion of the company's service offerings.
However, investors should note that while this is a positive development, it may not have an immediate impact on the company's financials. The real value lies in the long-term potential for securing government contracts and expanding Scorpius' footprint in the lucrative biodefense market.
Joining the Medical CBRN Defense Consortium positions Scorpius Holdings to tap into the lucrative government contracting space. This move could significantly expand the company's addressable market, particularly in high-priority areas of national security.
The consortium membership provides Scorpius with a competitive advantage in bidding for DoD contracts related to CBRN countermeasures. These contracts often involve substantial funding and can lead to long-term, stable revenue streams. However, the government contracting process is complex and highly competitive, requiring patience and resource investment.
Investors should monitor Scorpius' ability to leverage this opportunity into tangible contract wins. Success in this arena could transform the company's financial outlook, but it's important to temper short-term expectations as the process of securing and executing government contracts can be lengthy.
DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats.
The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solutions. Its mission is to rapidly advance research, development, and manufacturing of technologies that safeguard national security. As a member, Scorpius will contribute its proprietary scientific expertise and resources to accelerate innovations aimed at addressing CBRN threats.
“We are honored to be selected to join the Medical CBRN Defense Consortium, which plays a vital role in safeguarding public health against complex CBRN challenges,” said Jeff Wolf, CEO of Scorpius. “Our selection as a member reinforces our commitment to developing therapies that can protect both military personnel and civilians in the face of evolving threats.”
Membership in the consortium allows Scorpius to engage with government stakeholders, collaborate with other innovative companies and academic institutions, and pursue funding opportunities for projects aligned with the DoD’s medical CBRN defense priorities.
The Medical CBRN Defense Consortium includes organizations committed to the research and development of technologies and treatments for CBRN hazards. As Scorpius continues to advance its strategic initiatives, this selection represents a significant milestone in the company’s ongoing efforts to contribute to U.S. biosecurity and national defense.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as Scorpius contributing its proprietary scientific expertise and resources to accelerate innovations aimed at addressing CBRN threats and the selection to join the MCDC representing a significant milestone in the company’s ongoing efforts to contribute to U.S. biosecurity and national defense. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to derive the anticipated benefits from joining the MCDC; the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its pipeline and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
What is the significance of Scorpius Holdings (SCPX) joining the Medical CBRN Defense Consortium?
How does joining the MCDC align with Scorpius Holdings' (SCPX) business strategy?
What potential benefits could Scorpius Holdings (SCPX) gain from MCDC membership?
